Paclitex 6 mg/ml (IV Infusion)

Title

• Paclitex Injection

Categories

• Medicine
• Chemotherapy
• Cancer treatment

Description

• Paclitaxel is a novel anti-microtubule agent
• Promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules
• Indicated for various types of cancer including ovarian carcinoma, breast carcinoma, non-small cell lung carcinoma, Kaposi's sarcoma, and gastric carcinoma
• Administered intravenously in combination with other drugs

Dimensions

• Available in multiple vial sizes

Color options

• Clear liquid solution

Functions

• Treats advanced carcinoma of the ovary
• Adjuvant treatment of node-positive breast cancer
• First-line therapy for advanced or metastatic breast cancer
• Treatment for non-small cell lung cancer in patients who are not candidates for curative surgery and/or radiation therapy
• Second line treatment of AIDS related Kaposi's Sarcoma
• Treatment of Gastric Carcinoma

Materials

• Contains Paclitaxel
• May contain cimetidine
• May contain ranitidine
• May contain dexamethasone
• May contain diphenhydramine

Technical specifications

• Recommended dosages based on the type of cancer being treated
• Biphasic decline in plasma concentrations following intravenous administration
• Clearance not affected by cimetidine premedication
• Metabolized in part by cytochrome P450 isoenzymes CYP2C8 and CYP3A4
• Storage stability for up to 27 hours at ambient temperature

Design elements

• Packaged in vials
• Requires dilution in specific types of solutions prior to infusion

Usability features

• Requires premedication to prevent severe hypersensitivity reactions
• Should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents

Dosage recommendation

• First line and second line treatment dosages for ovarian cancer
• Adjuvant chemotherapy dosage for breast carcinoma
• First line and second line chemotherapy dosages for breast carcinoma
• Dosage for non-small-cell lung cancer
• Dosage for AIDS-related Kaposi's Sarcoma
• Dose adjustment based on individual patient tolerance

Interaction

• Clearance not affected by cimetidine premedication
• Interactions with cisplatin, doxorubicin, and active substances metabolized in the liver
• Caution required when administering concomitantly with certain medicines known to inhibit or induce specific cytochrome P450 isoenzymes

Contraindications

• Contraindicated in patients with severe hypersensitivity reactions or lactation
• Should not be used in patients with specific baseline neutrophil and platelet counts
• Contraindicated in patients with severe hepatic impairment

Side effects

• Common and rare side effects experienced by patients
• Includes low blood counts, hair loss, neuropathy, nausea, vomiting, diarrhea, hypersensitivity reactions, and more

Pregnancy lactation

• Category D pregnancy rating
• Contraindicated during lactation

Precautions warnings

• Administered under the supervision of experienced physician
• Significant hypersensitivity reactions and extravasation precautions
• Bone marrow suppression and neutrophil monitoring
• Severe cardiac conduction abnormalities reported rarely

Special populations

• Dosage recommendations for patients with severe neutropenia or hepatic impairment
• Not recommended for pediatric use

Overdose effects

• No known antidote for Paclitex overdose
• Primary anticipated toxicities include bone marrow suppression, peripheral neurotoxicity, and mucositis

Reconstitution

• Requires dilution prior to intravenous infusion
• Stable for up to 27 hours at ambient temperature and room lighting conditions
• Visual inspection required prior to administration

Storage conditions

• Store below 30°C and protect from light
• Use only freshly prepared solution

Related Brands

• Paclitaxel Sandoz 6 mg/ml (IV Infusion) - sandoz-a-novartis-division